Sunvozertinib received FDA priority review for NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy progression. The WU-KONG1 Part B study showed a 53.3% objective response ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback